Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/EML4_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EML4_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EML4_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/EML4_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EML4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EML4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/EML4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EML4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EML4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EML4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EML4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
GO:01400143 | Cervix | CC | mitotic nuclear division | 50/2311 | 287/18723 | 7.27e-03 | 3.91e-02 | 50 |
GO:00482851 | Cervix | CC | organelle fission | 78/2311 | 488/18723 | 9.70e-03 | 4.79e-02 | 78 |
GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
GO:0140014 | Colorectum | AD | mitotic nuclear division | 78/3918 | 287/18723 | 6.48e-03 | 4.05e-02 | 78 |
GO:00516561 | Colorectum | SER | establishment of organelle localization | 100/2897 | 390/18723 | 1.11e-07 | 6.79e-06 | 100 |
GO:00516562 | Colorectum | MSS | establishment of organelle localization | 115/3467 | 390/18723 | 7.30e-08 | 3.67e-06 | 115 |
GO:01400141 | Colorectum | MSS | mitotic nuclear division | 70/3467 | 287/18723 | 7.48e-03 | 4.72e-02 | 70 |
GO:00516563 | Colorectum | FAP | establishment of organelle localization | 97/2622 | 390/18723 | 5.91e-09 | 9.48e-07 | 97 |
GO:00516564 | Colorectum | CRC | establishment of organelle localization | 76/2078 | 390/18723 | 6.53e-07 | 4.50e-05 | 76 |
GO:00516568 | Endometrium | AEH | establishment of organelle localization | 77/2100 | 390/18723 | 4.89e-07 | 1.94e-05 | 77 |
GO:005165613 | Endometrium | EEC | establishment of organelle localization | 75/2168 | 390/18723 | 6.23e-06 | 1.49e-04 | 75 |
GO:005165616 | Esophagus | HGIN | establishment of organelle localization | 90/2587 | 390/18723 | 4.27e-07 | 1.94e-05 | 90 |
GO:00500003 | Esophagus | HGIN | chromosome localization | 24/2587 | 82/18723 | 2.07e-04 | 3.82e-03 | 24 |
GO:01400146 | Esophagus | HGIN | mitotic nuclear division | 61/2587 | 287/18723 | 3.38e-04 | 5.55e-03 | 61 |
GO:00070593 | Esophagus | HGIN | chromosome segregation | 71/2587 | 346/18723 | 3.47e-04 | 5.62e-03 | 71 |
GO:00513033 | Esophagus | HGIN | establishment of chromosome localization | 23/2587 | 80/18723 | 3.71e-04 | 5.77e-03 | 23 |
GO:00070803 | Esophagus | HGIN | mitotic metaphase plate congression | 15/2587 | 50/18723 | 2.35e-03 | 2.39e-02 | 15 |
GO:00513103 | Esophagus | HGIN | metaphase plate congression | 18/2587 | 65/18723 | 2.46e-03 | 2.45e-02 | 18 |
GO:00000703 | Esophagus | HGIN | mitotic sister chromatid segregation | 36/2587 | 168/18723 | 4.42e-03 | 3.87e-02 | 36 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052234 | Cervix | CC | Non-small cell lung cancer | 21/1267 | 72/8465 | 1.48e-03 | 6.32e-03 | 3.74e-03 | 21 |
hsa0522313 | Cervix | CC | Non-small cell lung cancer | 21/1267 | 72/8465 | 1.48e-03 | 6.32e-03 | 3.74e-03 | 21 |
hsa05223 | Colorectum | FAP | Non-small cell lung cancer | 20/1404 | 72/8465 | 1.14e-02 | 3.92e-02 | 2.38e-02 | 20 |
hsa052231 | Colorectum | FAP | Non-small cell lung cancer | 20/1404 | 72/8465 | 1.14e-02 | 3.92e-02 | 2.38e-02 | 20 |
hsa052356 | Esophagus | ESCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa052237 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa0523511 | Esophagus | ESCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 58/4205 | 89/8465 | 2.19e-03 | 6.16e-03 | 3.16e-03 | 58 |
hsa0522316 | Esophagus | ESCC | Non-small cell lung cancer | 48/4205 | 72/8465 | 2.57e-03 | 7.05e-03 | 3.61e-03 | 48 |
hsa052232 | Liver | HCC | Non-small cell lung cancer | 46/4020 | 72/8465 | 3.61e-03 | 1.12e-02 | 6.22e-03 | 46 |
hsa0522311 | Liver | HCC | Non-small cell lung cancer | 46/4020 | 72/8465 | 3.61e-03 | 1.12e-02 | 6.22e-03 | 46 |
hsa052233 | Lung | IAC | Non-small cell lung cancer | 17/1053 | 72/8465 | 6.15e-03 | 2.60e-02 | 1.72e-02 | 17 |
hsa0522312 | Lung | IAC | Non-small cell lung cancer | 17/1053 | 72/8465 | 6.15e-03 | 2.60e-02 | 1.72e-02 | 17 |
hsa05235 | Oral cavity | OSCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 56/3704 | 89/8465 | 1.97e-04 | 6.55e-04 | 3.33e-04 | 56 |
hsa052236 | Oral cavity | OSCC | Non-small cell lung cancer | 46/3704 | 72/8465 | 4.37e-04 | 1.32e-03 | 6.72e-04 | 46 |
hsa052351 | Oral cavity | OSCC | PD-L1 expression and PD-1 checkpoint pathway in cancer | 56/3704 | 89/8465 | 1.97e-04 | 6.55e-04 | 3.33e-04 | 56 |
hsa0522315 | Oral cavity | OSCC | Non-small cell lung cancer | 46/3704 | 72/8465 | 4.37e-04 | 1.32e-03 | 6.72e-04 | 46 |
hsa052352 | Oral cavity | EOLP | PD-L1 expression and PD-1 checkpoint pathway in cancer | 32/1218 | 89/8465 | 2.96e-07 | 3.18e-06 | 1.88e-06 | 32 |
hsa0522322 | Oral cavity | EOLP | Non-small cell lung cancer | 19/1218 | 72/8465 | 5.29e-03 | 1.63e-02 | 9.60e-03 | 19 |
hsa052353 | Oral cavity | EOLP | PD-L1 expression and PD-1 checkpoint pathway in cancer | 32/1218 | 89/8465 | 2.96e-07 | 3.18e-06 | 1.88e-06 | 32 |
hsa0522332 | Oral cavity | EOLP | Non-small cell lung cancer | 19/1218 | 72/8465 | 5.29e-03 | 1.63e-02 | 9.60e-03 | 19 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | TAE226 | | 26090892 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | Sirolimus | SIROLIMUS | 21613408 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | AZD3463 | | 27009859 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | Crizotinib | CRIZOTINIB | 26775591,27009859,22277784,20979469,22235099,28476735,27354483,27432227,25228534,26698910,21613408,26554404,23344087,21791641,27780853,24675041 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | Alectinib | ALECTINIB | 27009859,28476735,25393796,26849637,27432227,26682573,25228534,21575866,26698910,23344087 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | AUY922 | | 26698910 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | PF-06463922 | LORLATINIB | 27432227,26698910,26144315,26554404 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | Afatinib | AFATINIB | 26682573 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | X-396 | ENSARTINIB | 21613408 |
27436 | EML4 | CLINICALLY ACTIONABLE, KINASE | | AP26113 | CHEMBL3397300 | 27009859,27432227,25228534,26698910,27780853 |